Evaluation of Schemes of Administration of Intravenous Ketamine in Depression

Treatment Resistant Depression Clinical Trial

Official title:

Evaluation of Schemes of Administration of Intravenous Ketamine in Treatment-resistant Depression: Clinical-neuroimaging Correlation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03742557
• Other study ID #: 74/18
• Status: Recruiting
• Phase: Phase 3
• Start date: October 1, 2018
• Est. completion date: January 1, 2020

Study information

• Verified date: September 2019
• Source: National Institute of Neurology and Neurosurgery, Mexico
• Contact: Rodrigo Pérez-Esparza, M.D., M.Sc.
• Phone: +5256063822
• Email: dr.rodrigope[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Mexico, prevalence reported for major depressive disorder (MDD) is of 7.2%. It is currently in the top 5 causes of disability worldwide. One third of patients will not achieve remission after two treatments, being classified as treatment-resistant. In a neurochemical level, evidence shows dysregulation of the excitatory neurotransmitter Glutamate in patients with MDD. Chronic stress has been related to this dysregulation. Ketamine, has shown to regulate glutamatergic neurotransmission, and specially promote the release and production of neurotrophic factors key in the causes of MDD inhibited by glutamate dysregulation), and allow restoration of areas affected.

Clinical studies of ketamine in MDD have shown robust, durable , and rapid effects (during the first 4-24 hours), allowing a great opportunity for patients who do not achieve benefits from antidepressants or patients with suicidal ideation . These results have been reported in metaanalysis.

To our knowledge, there are no studies using Magnetic Resonance Spectroscopy, in areas related to MDD, after a series of ketamine administrations, which we think may show changes after this chronic administration and explain its antidepressant properties.

Goals: Provide clinical evidence of responseas well as a neurological basis or biomarker of response to a series of ketamine infusions.

Description:

1. Background 1.1 Major depressive disorder (MDD) MDD is a clinical syndrome characterized by the presence of low modo, anhedonia, appetite and weight changes, sleep disturbances, psychomotor alterations, fatigue, guilt and low self-esteem, ideas related to death or suicide, and concentration difficulties.

MDD represents one of the first causes of disability worldwide. In Mexico, prevalence is estimated in 7.2% of the population. In accordance to the largest clinical trial of MDD, the STAR*D (Sequenced Treatment Alternatives to Relieve Depression), up to one third of the patients will not achieve remission after 4 treatment strategies. These obligates research of new treatments for MDD and treatment-resistant depression TRD.

1.2 Treatment-resistant Depression (TRD) There is a lack of consensus to define TRD, with multiple criteria used by distinct authors. However, the most used definition is the failure to achieve response or remission after two consecutive treatments at an adequate dose and duration, considering the last episode.

1.3 Physiopathology of MDD. Historically, serotonin and noradrenaline disturbances in production, metabolism and reuptake have been implicated in MDD, as well as dopamine. However, this hypothesis seems insufficient in explaining the lack of immediate response, and the lack of response of up to one third of patients.

It is necessary to understand MDD as a multifactorial disorder (biological, psychological, and environmental agents). At a genetic level, some polymorphisms have been related to the appearance of MDD, such as the gen associated with the glucocorticoid receptor NR3C1, the one related to the monoaminooxidase-A, and the one related to the glucogen kinase-synthase 3. Heredability for MDD has been calculated around 37%.

In a molecular basis, there are three principal factors implicated in the genesis of MDD:

neurotrophic factors such as brain-derived neurotrophic factor (BDNF), proinflammatory cytokines (interleukin-1 beta, 6, tumoral necrosis factor alpha), and a dysregulation in the hypothalamus-hypophysis-adrenal axis.

Anatomically speaking, the majority of neuroimaging studies converge in the existence of a hyperactive amygdala, ventral striatum and medial prefrontal cortex to negative stimuli. Among regions of major interest are the amygdala, prefrontal cortex, the cingulate gyrus in its subgenual area and anterior or pregenual area (pgACC), ventral striatum, medial thalamus, posterior cingulate gyrus and anterior insulae.

1.5 Glutamate and GABA in MDD y GABA Glutamatergic and GABAergic dysfunction in affective disorders has increased interest in the last years, evidenced by clinical neuroimaging studies that demonstrate disturbances in such systems in patients with MDD, animal models of stress, and the role of glucocorticoids in the glutamatergic regulation secondary to chronic stress, as well as studies about the action of antidepressants in these systems.

1.6 Magnetic Resonance Spectroscopy H1-MRS in MDD H1-MRS studies coincide with the diminution of glutamate, glutamine and Glx (a composite measure of the previous two) in patients with MDD compared to controls in the pgCCA. Such finding has been correlated with the severity of MDD and anomalous connectivity with the anterior insulae.

Disturbed GABA neurotransmission has been also found in the occipital cortex in patients with MDD and TRD, suggesting a possible biomarker for differential diagnosis. Specifically in TRD patients, Glx in pgACC have been found to be altered, however more studies are needed.

1.7 pgACC in MDD pgACC in MDD refers to the rostral portion of the ACC that englobes the anterior portion of the corpus callosum, nominated sometimes as the medial prefrontal cortex. It comprises Brodmann's areas 24, 25, 32 and 33. The pgACC corresponds to the area 33. Through models of meta-analytic connectivity, its role in the production of interception and subjective feelings, coordinating responses appropriate to internal and external events along with the insulae, and its involvement in the representation of interoceptive information have been confirmed. It seems also to represent the area in with the distinction of cognition and affect takes place39. Such function is supported by evidence of structures connected to the pgACC (lateral and ventromedial prefrontal cortices, and limbic regions).

pgACC activity has been shown to be a predictor of response of some depression treatments such as pharmacological treatments and transcranial magnetic stimulation.

Functional MRI (fMRI), has demonstrated an increased connectivty between pgACC and dorsolateral prefrontal cortex, as well as a diminution in the connectivity of the pgACC and caudate. Such findings may be explained by an intense cognitive control over emotional regulation in MDD patients.

There is evidence of abnormal glutamatergic abnormalities in cerebral activity in resting state in MDD patients, finding a correlation between lower glutamate levels in the pgACC and a diminished connectivity of the same area with the anterior insulae compared to controls through H1-MRS and BOLD techniques.

Because of these findings, it is of great interest for the investigators to study this region in relation to ketamine interventions as an antidepressant therapy.

1.9 Ketamine as an antidepressant Ever since the first clinical study reporting the use of ketamine as an antidepressant for TRD patients, showing a rapid (in hours) and robust (in days) response after a unique administration, the literature has grown exponentially. However, mechanisms of action remain inconclusive.

Its antidepressant properties have been vinculated by ketamine's capacity to stimulate the release and expression of BDNF. Contrary to the result of chronic stress, inhibiting these results, ketamine seems to stimulate it. This molecule is involved in the modulation of neuroplasticity, specifically in the prefrontal cortices. Another of the explanations in a molecular level has been its regulation in the glycogen kinase-synthase 3 (GSK3), required for the pruning and synaptic reconsolidation50. Finally, ketamine has been shown to regulate the lateral habenula (implicated in MDD), probably also explaining its role in the down-regulation of monoamines.

Its clinical effects make ketamine a candidate to solve problems related to MDD in public health, confirmed by various systematic reviews and meta-analysis.

There are clinical trials reporting the efficacy of repeated administrations of ketamine (from 7 days up to 83 days after the last administration) with IV ketamine and intranasal esketamine. However, studies vary in the number of interventions, intervals, conditions to continue treatment, times of measurements, follow-up, making it impossible to obtain standardized results. Also, repeated doses have not been reported with H1-MRS technique to explore if there are durable changes after chronic administration of subanesthetic doses of ketamine in MDD.

1.10 Glutamatergic and GABAergic chances in pgACC before ketamine administration H1-MRS data concerning glutamate levels in healthy subjects show that after ketamine administration, there is a significative increase in glutamate in the pgACC, correlating with psychopathology scales such as the PANSS, supporting the idea that ketamine exerts an important effect in the neurotransmission related to its mechanism of action in this region of interest. Such findings propose the difference in this region of interest pre and postinfusion of ketamine and represent an important antecedent for the current proposal. In a similar way, in healthy subjects, hippocampal augments of Glx and a decreased of the fronto-temporal connectivity and temporo-parietal after the administration measured at 10 minutes after ketamine administration has been shown.

When measuring glutamate, Glx and GABA in the pgACC after ketamine in MDD patients, there have been mixed results. Some authors have found a significative increase of the same, correlating with clinical response when measuring during the infusion53. However, using major tesla MRI and measuring the effect of ketamine in glutamate at 24 hours after administration show no differences against placebo. Both findings are discussed concerning the time of measure, concluding that there is a rapid and robust increase, but a transitory one. However these changes do not persist.

To our knowledge no H1-MRS studies after a series of ketamine infusions to know if there are durable changes in glutamate of GABA levels that may explain the durable antidepressant effects of ketamine.

1.11 Experience in the National Institute of Neurology and Neurosurgery (NINN), Mexico Clinical experience with ketamine as an antidepressant and augmentation agent to conventional antidepressants has shown similar clinical results as reported previously, and even have shown longer times until relapse. There is extensive experience in the utilization of H1-MRS in other disorders. The investigators consider that this institution is ideal for the development of the current proposal.

2.1 Key questions

1. Will patients with TRD have a clinical response (50%) after the infusion of ketamine as measured by the Hamilton Depression Rating Scale (HDRS) and the Montgomery-Asberg Depression Rating Scale (MADRS) during the first 24 hours, and different to patients receiving placebo?

2. Will TRD patients presenting response, present a significant increase in Glutamate and GABA in the pgACC measured by H1-MRS 24 hours after the last intervention, compared to the basal measure?

3. Will this response, if achieved, be different than changes in Glutamate and GABA in the pgACC among patients receiving placebo?

3. METHODOLOGY 3.1 Design A double-blind randomized clinical trial will be performed 3.2 Sample During the sample selection, inclusion and exclusion criteria defined afterwards will be used. Sampling will be non-probabilistic in a consecutive case manner. Patients will participate voluntarily after informed consent is achieved.

Subjects treated in the NINN will be divided in two groups:

1. Subjects with TRD, receiving ketamine infusions from start.

2. Subjects with TRD, receiving placebo (saline solution 0.9%), and afterwards

3.3 Procedure

1. Sampling.

2. Previous evaluation:

1. Psychiatric evaluation (HDRS-17, MADRS).

2. Medical evaluation

3. Randomization

4. Basal 1H-MRS for GABA:

5. Basal 1H-MRS for Glutamate:

Similar to the GABA acquisition.

6. Interventions

1. All interventions will be done as an out-patient basis by a psychiatrist.

2. A 0.5 mg/kg infusion of ketamine or placebo IV along 40 minutes will be performed. Vigilance will be strict (vital signs, adverse effects, subjective experience, clinimetry).

3. After every intervention, the patient will be observed for 1 hour or more if considered necessary by the clinician, returning to their normal routine afterward.

4. Such intervention will be done twice weekly in a prior of 4 weeks (day 1, 4, 8, 11, 15, 19, 23, and 27) for a total of 8 infusions in patients receiving ketamine.

i. In case of having received placebo, patients will then receive 8 infusions of ketamine.

ii. In case of having received ketamine, they will continue until completing 8 infusions, and then receive 4 infusions of placebo.

7. Posterior evaluation

1. Psychiatric evaluation as explained earlier at 4, 24, 72 hours and weekly up to 12 weeks after the last infusion of relapse.

2. Glutamate and GABA in pgACC measures with the parameters after 10 minutes of starting the infusion, 24 hours after, and 1 week after the last infusion of ketamine or placebo.

8. Follow-up a. 12-week follow-up after last intervention or relapse, after which patients will end participation and their care will continue as usual.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: January 1, 2020
• Est. primary completion date: January 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Age: 18-65 years

2. MDD diagnosis as provided by DSM-5 criteria

3. TRD as defined by failure to achieve response to two consecutive antidepressant therapies at an adequate dose and duration

4. Patients approving inclusion by signing the informed consent

Exclusion Criteria:

1. Comorbidity with other mental and neurological disorders (except generalized anxiety disorder)

2. Substance use disorders at least 3 months prior to enrollment

3. Evidence of structural abnormalities in basal MRI

4. Pregnancy or lactation

5. Hypersensitivity to ketamine

6. Cardiac failure

7. Personal history of psychosis

8. First-degree relatives with history of psychosis

9. Uncontrolled close-angle glaucoma

10. Neurological disease (present)

11. Uncontrolled Hypertension

12. Contraindications for the realization of H1-MRS.

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Treatment-Resistant
• Treatment Resistant Depression

Intervention

Drug:
• Ketamine 50 MG/ML Injectable Solution, 0.5 mg/kg IV
Ketamine 0.5 mg/kg IV

Locations

Country	Name	City	State
Mexico	Instituto Nacional de Neurología y Neurocirugía (National Institute of Neurology and Neurosurgery)	Mexico City	Tlalpan

Sponsors (1)

Lead Sponsor	Collaborator
National Institute of Neurology and Neurosurgery, Mexico

Country where clinical trial is conducted

Mexico, 

References & Publications (74)

American Psychiatric Association., American Psychiatric Association. DSM-5 Task Force. Diagnostic and statistical manual of mental disorders : DSM-5. 5th ed. Arlington, VA: American Psychiatric Association; 2013.

Berlim MT, Turecki G. What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials. Eur Neuropsychopharmacol. 2007 Nov;17(11):696-707. Epub 2007 May 23. Review. — View Citation

Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000 Feb 15;47(4):351-4. — View Citation

Boku S, Nakagawa S, Toda H, Hishimoto A. Neural basis of major depressive disorder: Beyond monoamine hypothesis. Psychiatry Clin Neurosci. 2018 Jan;72(1):3-12. doi: 10.1111/pcn.12604. Epub 2017 Oct 19. Review. — View Citation

Caddy C, Amit BH, McCloud TL, Rendell JM, Furukawa TA, McShane R, Hawton K, Cipriani A. Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Syst Rev. 2015 Sep 23;(9):CD011612. doi: 10.1002/14651858.CD011612.pub2. R — View Citation

Cohen MG, Chan SL, Bhargava HN, Trevor AJ. Inhibition of mammalian brain acetylcholinesterase by ketamine. Biochem Pharmacol. 1974 May 1;23(11):1647-52. — View Citation

Conway CR, George MS, Sackeim HA. Toward an Evidence-Based, Operational Definition of Treatment-Resistant Depression: When Enough Is Enough. JAMA Psychiatry. 2017 Jan 1;74(1):9-10. doi: 10.1001/jamapsychiatry.2016.2586. — View Citation

Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC, Thase ME, Winokur A, Van Nueten L, Manji H, Drevets WC. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clin — View Citation

Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008 Jan;9(1):46-56. Review. — View Citation

Davey CG, Harrison BJ, Yücel M, Allen NB. Regionally specific alterations in functional connectivity of the anterior cingulate cortex in major depressive disorder. Psychol Med. 2012 Oct;42(10):2071-81. doi: 10.1017/S0033291712000323. — View Citation

de la Fuente-Sandoval C, Reyes-Madrigal F, Mao X, León-Ortiz P, Rodríguez-Mayoral O, Jung-Cook H, Solís-Vivanco R, Graff-Guerrero A, Shungu DC. Prefrontal and Striatal Gamma-Aminobutyric Acid Levels and the Effect of Antipsychotic Treatment in First-Episo — View Citation

de la Fuente-Sandoval C, Reyes-Madrigal F, Mao X, León-Ortiz P, Rodríguez-Mayoral O, Solís-Vivanco R, Favila R, Graff-Guerrero A, Shungu DC. Cortico-Striatal GABAergic and Glutamatergic Dysregulations in Subjects at Ultra-High Risk for Psychosis Investiga — View Citation

de la Fuente-Sandoval C. Potential Regional Differences in GABA Levels in Patients With Psychosis Compared With Control Subjects. Am J Psychiatry. 2016 Jul 1;173(7):734. doi: 10.1176/appi.ajp.2016.16030261. — View Citation

Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, Machado-Vieira R, Manji HK, Zarate CA Jr. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistan — View Citation

DiazGranados N, Ibrahim LA, Brutsche NE, Ameli R, Henter ID, Luckenbaugh DA, Machado-Vieira R, Zarate CA Jr. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major dep — View Citation

Drevets WC, Savitz J, Trimble M. The subgenual anterior cingulate cortex in mood disorders. CNS Spectr. 2008 Aug;13(8):663-81. Review. — View Citation

Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012 Oct 5;338(6103):68-72. doi: 10.1126/science.1222939. Review. — View Citation

Duman RS, Voleti B. Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci. 2012 Jan;35(1):47-56. doi: 10.1016/j.tins.2011.11.004. Review. — View Citation

Espinosa-Aguilar C-A, Zamora-Olvera, Arronte-Rosales, Krug-Llamas, Olivares-Santos, Reyes-Morales, Tapia-Garcia, Garcia-Gonzalez, Doubova. Guía de práctica clínica para el diagnóstico y tratamiento de depresión en los adultos mayores. Salud Mental. 2007;3

Evans JW, Lally N, An L, Li N, Nugent AC, Banerjee D, Snider SL, Shen J, Roiser JP, Zarate CA Jr. 7T (1)H-MRS in major depressive disorder: a Ketamine Treatment Study. Neuropsychopharmacology. 2018 Aug;43(9):1908-1914. doi: 10.1038/s41386-018-0057-1. Epub — View Citation

Fond G, Loundou A, Rabu C, Macgregor A, Lançon C, Brittner M, Micoulaud-Franchi JA, Richieri R, Courtet P, Abbar M, Roger M, Leboyer M, Boyer L. Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology (Be — View Citation

GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burd — View Citation

Greicius MD, Flores BH, Menon V, Glover GH, Solvason HB, Kenna H, Reiss AL, Schatzberg AF. Resting-state functional connectivity in major depression: abnormally increased contributions from subgenual cingulate cortex and thalamus. Biol Psychiatry. 2007 Se — View Citation

Hamani C, Mayberg H, Stone S, Laxton A, Haber S, Lozano AM. The subcallosal cingulate gyrus in the context of major depression. Biol Psychiatry. 2011 Feb 15;69(4):301-8. doi: 10.1016/j.biopsych.2010.09.034. Epub 2010 Dec 8. Review. — View Citation

Harmer CJ, Duman RS, Cowen PJ. How do antidepressants work? New perspectives for refining future treatment approaches. Lancet Psychiatry. 2017 May;4(5):409-418. doi: 10.1016/S2215-0366(17)30015-9. Epub 2017 Jan 31. Review. — View Citation

Heinze C. Gui´a cli´nica para el Manejo de la Depresio´n. In: Psiquiatri´a INd, ed. Gui´as Cli´nicas para la Atencio´n de Trastornos Mentales. Mexico D.F.2010.

Hirschfeld RM. The epidemiology of depression and the evolution of treatment. J Clin Psychiatry. 2012;73 Suppl 1:5-9. doi: 10.4088/JCP.11096su1c.01. Review. — View Citation

Hock RS, Or F, Kolappa K, Burkey MD, Surkan PJ, Eaton WW. A new resolution for global mental health. Lancet. 2012 Apr 14;379(9824):1367-8. doi: 10.1016/S0140-6736(12)60243-8. — View Citation

Horn DI, Yu C, Steiner J, Buchmann J, Kaufmann J, Osoba A, Eckert U, Zierhut KC, Schiltz K, He H, Biswal B, Bogerts B, Walter M. Glutamatergic and resting-state functional connectivity correlates of severity in major depression - the role of pregenual ant — View Citation

Kessler RC, Angermeyer M, Anthony JC, DE Graaf R, Demyttenaere K, Gasquet I, DE Girolamo G, Gluzman S, Gureje O, Haro JM, Kawakami N, Karam A, Levinson D, Medina Mora ME, Oakley Browne MA, Posada-Villa J, Stein DJ, Adley Tsang CH, Aguilar-Gaxiola S, Alons — View Citation

Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS; National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. — View Citation

Kishimoto T, Chawla JM, Hagi K, Zarate CA, Kane JM, Bauer M, Correll CU. Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectorie — View Citation

Kraguljac NV, Frölich MA, Tran S, White DM, Nichols N, Barton-McArdle A, Reid MA, Bolding MS, Lahti AC. Ketamine modulates hippocampal neurochemistry and functional connectivity: a combined magnetic resonance spectroscopy and resting-state fMRI study in h — View Citation

Kupfer DJ, Frank E, Phillips ML. Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet. 2012 Mar 17;379(9820):1045-55. doi: 10.1016/S0140-6736(11)60602-8. Epub 2011 Dec 19. Review. — View Citation

Lener MS, Niciu MJ, Ballard ED, Park M, Park LT, Nugent AC, Zarate CA Jr. Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine. Biol Psychiatry. 2017 May 15;81(10):886-897. doi: 1 — View Citation

Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BW, Zitman FG. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010 Mar;67(3):220-9. doi: 10.1001/archgenpsychiatry.20 — View Citation

Luykx JJ, Laban KG, van den Heuvel MP, Boks MP, Mandl RC, Kahn RS, Bakker SC. Region and state specific glutamate downregulation in major depressive disorder: a meta-analysis of (1)H-MRS findings. Neurosci Biobehav Rev. 2012 Jan;36(1):198-205. doi: 10.101 — View Citation

MacQueen G, Frodl T. The hippocampus in major depression: evidence for the convergence of the bench and bedside in psychiatric research? Mol Psychiatry. 2011 Mar;16(3):252-64. doi: 10.1038/mp.2010.80. Epub 2010 Jul 27. Review. — View Citation

Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, Schwalb JM, Kennedy SH. Deep brain stimulation for treatment-resistant depression. Neuron. 2005 Mar 3;45(5):651-60. — View Citation

McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med. 2015 Mar;45(4):693-704. d — View Citation

Medina-Mora ME, Borges G, Benjet C, Lara C, Berglund P. Psychiatric disorders in Mexico: lifetime prevalence in a nationally representative sample. Br J Psychiatry. 2007 Jun;190:521-8. — View Citation

Milak MS, Proper CJ, Mulhern ST, Parter AL, Kegeles LS, Ogden RT, Mao X, Rodriguez CI, Oquendo MA, Suckow RF, Cooper TB, Keilp JG, Shungu DC, Mann JJ. A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to — View Citation

Mosebach J, Keilhoff G, Gos T, Schiltz K, Schoeneck L, Dobrowolny H, Mawrin C, Müller S, Schroeter ML, Bernstein HG, Bogerts B, Steiner J. Increased nuclear Olig1-expression in the pregenual anterior cingulate white matter of patients with major depressio — View Citation

Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet. 2007 Sep 8;370(9590):851-8. — View Citation

Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, Iqbal S, Pillemer S, Foulkes A, Shah A, Charney DS, Mathew SJ. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J — View Citation

Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M, Collins KA, Mathew SJ, Charney DS, Iosifescu DV. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2 — View Citation

Musazzi L, Treccani G, Mallei A, Popoli M. The action of antidepressants on the glutamate system: regulation of glutamate release and glutamate receptors. Biol Psychiatry. 2013 Jun 15;73(12):1180-8. doi: 10.1016/j.biopsych.2012.11.009. Epub 2012 Dec 28. R — View Citation

Nugent AC, Diazgranados N, Carlson PJ, Ibrahim L, Luckenbaugh DA, Brutsche N, Herscovitch P, Drevets WC, Zarate CA Jr. Neural correlates of rapid antidepressant response to ketamine in bipolar disorder. Bipolar Disord. 2014 Mar;16(2):119-28. doi: 10.1111/ — View Citation

Nutt DJ. The neuropharmacology of serotonin and noradrenaline in depression. Int Clin Psychopharmacol. 2002 Jun;17 Suppl 1:S1-12. Review. — View Citation

Pérez-Esparza R, Corona T, Ruiz-García RG, Oñate-Cadena N, de la Fuente-Sandoval C, Ramírez-Bermúdez J. Time until relapse after augmentation with single-dose ketamine in treatment-resistant depression. Psychiatry Clin Neurosci. 2018 Aug;72(8):623. doi: 1 — View Citation

Pérez-Esparza R. Ketamine for Treatment-Resistant Depression: a New Advocate. Rev Invest Clin. 2018;70(2):65-7. doi: 10.24875/RIC.18002501. — View Citation

Pérez-Esparza R. Tratamiento farmacológico de la depresión: actualidades y futuras direcciones. Revista de la Facultad de Medicina. 2017;60(5):7-16.

Price RB, Shungu DC, Mao X, Nestadt P, Kelly C, Collins KA, Murrough JW, Charney DS, Mathew SJ. Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder. Biol Psychi — View Citation

Raison CL, Borisov AS, Majer M, Drake DF, Pagnoni G, Woolwine BJ, Vogt GJ, Massung B, Miller AH. Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol Psychiatry. 2009 Feb 15;65(4): — View Citation

Rasmussen KG, Lineberry TW, Galardy CW, Kung S, Lapid MI, Palmer BA, Ritter MJ, Schak KM, Sola CL, Hanson AJ, Frye MA. Serial infusions of low-dose ketamine for major depression. J Psychopharmacol. 2013 May;27(5):444-50. doi: 10.1177/0269881113478283. Epu — View Citation

Romeo B, Choucha W, Fossati P, Rotge JY. Meta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression. Psychiatry Res. 2015 Dec 15;230(2):682-8. doi: 10.1016/j.psychres.2015.10.032. Epub 2015 Oct 30. — View Citation

Rowland LM, Bustillo JR, Mullins PG, Jung RE, Lenroot R, Landgraf E, Barrow R, Yeo R, Lauriello J, Brooks WM. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am J Psychiatry. 2005 Feb;162(2):394-6. — View Citation

Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M. Acute and longer-term outcomes in depressed outpatients requiring on — View Citation

Savitz JB, Rauch SL, Drevets WC. Clinical application of brain imaging for the diagnosis of mood disorders: the current state of play. Mol Psychiatry. 2013 May;18(5):528-39. doi: 10.1038/mp.2013.25. Epub 2013 Apr 2. Review. — View Citation

Shiroma PR, Johns B, Kuskowski M, Wels J, Thuras P, Albott CS, Lim KO. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. J Affect Disord. 2014 Feb;155:123-9. doi: 10.1016/j.jad.2013.10.0 — View Citation

Singh I, Morgan C, Curran V, Nutt D, Schlag A, McShane R. Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight. Lancet Psychiatry. 2017 May;4(5):419-426. doi: 10.1016/S2215-0366(17)30102-5. Epub 2017 Apr 5. Review — View Citation

Singh JB, Fedgchin M, Daly EJ, De Boer P, Cooper K, Lim P, Pinter C, Murrough JW, Sanacora G, Shelton RC, Kurian B, Winokur A, Fava M, Manji H, Drevets WC, Van Nueten L. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous K — View Citation

Smith DJ, Azzaro AJ, Zaldivar SB, Palmer S, Lee HS. Properties of the optical isomers and metabolites of ketamine on the high affinity transport and catabolism of monoamines. Neuropharmacology. 1981 Apr;20(4):391-6. — View Citation

Smith DJ, Pekoe GM, Martin LL, Coalgate B. The interaction of ketamine with the opiate receptor. Life Sci. 1980 Mar 10;26(10):789-95. — View Citation

Stone JM, Dietrich C, Edden R, Mehta MA, De Simoni S, Reed LJ, Krystal JH, Nutt D, Barker GJ. Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology. Mol Psychiatry. 2012 Jul;17(7):664-5. doi: 10. — View Citation

Sullivan PF, Daly MJ, O'Donovan M. Genetic architectures of psychiatric disorders: the emerging picture and its implications. Nat Rev Genet. 2012 Jul 10;13(8):537-51. doi: 10.1038/nrg3240. Review. — View Citation

Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M; STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measur — View Citation

Valentine GW, Mason GF, Gomez R, Fasula M, Watzl J, Pittman B, Krystal JH, Sanacora G. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res. 2011 Fe — View Citation

Vande Voort JL, Morgan RJ, Kung S, Rasmussen KG, Rico J, Palmer BA, Schak KM, Tye SJ, Ritter MJ, Frye MA, Bobo WV. Continuation phase intravenous ketamine in adults with treatment-resistant depression. J Affect Disord. 2016 Dec;206:300-304. doi: 10.1016/j — View Citation

Weber M, Motin L, Gaul S, Beker F, Fink RH, Adams DJ. Intravenous anaesthetics inhibit nicotinic acetylcholine receptor-mediated currents and Ca2+ transients in rat intracardiac ganglion neurons. Br J Pharmacol. 2005 Jan;144(1):98-107. Erratum in: Br J Ph — View Citation

Wijeratne C, Sachdev P. Treatment-resistant depression: critique of current approaches. Aust N Z J Psychiatry. 2008 Sep;42(9):751-62. doi: 10.1080/00048670802277206. Review. — View Citation

Yang Y, Cui Y, Sang K, Dong Y, Ni Z, Ma S, Hu H. Ketamine blocks bursting in the lateral habenula to rapidly relieve depression. Nature. 2018 Feb 14;554(7692):317-322. doi: 10.1038/nature25509. — View Citation

Zarate CA Jr, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, Selter J, Marquardt CA, Liberty V, Luckenbaugh DA. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psych — View Citation

Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006 Aug;63(8):856-64. — View Citation

* Note: There are 74 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Depression Severity Hamilton Depression Rating Scale	Depression Severity (10 - 13 mild; 14-17 mild to moderate; >17 moderate to severe). Higher values represent a worse severity, but not necessarily outcome.	4, 24, 72 hours, weekly up to 12 weeks or until relapse (Change from baseline to each measure)
Primary	Glutamate	Glutamate levels in the pgACC basal and after the last intervention with ketamine or placebo	Basal, 10 minutes during intervention, 24 hours after, 4 weeks after (Change from baseline to each measure)
Primary	GABA	GABA levels in the pgACC basal and after the last intervention with ketamine or placebo	Basal, 10 minutes during intervention, 24 hours after, 4 weeks after (Change from baseline to each measure)
Primary	Depression Severity Montgomery-Asberg Depression Rating Scale)	Depression Severity (9-17 = mild, 18-34 = moderate, and = 35 = severe)	4, 24, 72 hours, weekly up to 12 weeks or until relapse (Change from baseline to each measure). Higher values represent a worse severity, but not necessarily outcome.